Latest News for BRIBF
- Final results from the ENSURE study demonstrate that the addition of elebsiran resulted in a higher functional cure rate compared with pegylated interferon alfa (PEG-IFNα) alone - Data from Cohort 4 suggested that participants responding to prior BRII ‑ 179 treatment achieved the most robust functional cure outcomes, further supporting its potential clinical benefit - Data from an ENSURE translational study…
- Participants achieving HBsAg loss with pegylated interferon alfa (PEG-IFNα) ± elebsiran or BRII-179 demonstrated favorable off-treatment clinical outcomes, with most HBsAg rebounds
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for BRIBF.
Senate Trading
No Senate trades found for BRIBF.
U.S. House Trading
No House trades found for BRIBF.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.